Non-receptor protein tyrosine kinases signaling pathways in normal and cancer cells

References

• Hubbard SR, Till JH. Protein tyrosine kinase structure and function. Annu Rev Biochem 2000;69:373–98
   PubMed Web of Science ®Google Scholar
• Manning G, Whyte DB, Martinez R, et al. The protein kinase complement of the human genome. Science 2002;298:1912–34
   PubMed Web of Science ®Google Scholar
• Schenk PW, Snaar-Jagalska BE. Signal perception and transduction: the role of protein kinases. Biochim Biophys Acta 1999;1449:1–24
   PubMed Web of Science ®Google Scholar
• Chang YM, Kung HJ, Evans CP. Nonreceptor tyrosine kinases in prostate cancer. Neoplasia 2007;9:90–100
   PubMed Web of Science ®Google Scholar
• Malarkey K, Belham CM, Paul A, et al. The regulation of tyrosine kinase signalling pathways by growth factor and G-protein-coupled receptors. Biochem J 1995;309:361–75
   PubMed Web of Science ®Google Scholar
• Kawakami T, Pennington CY, Robbins KC. Isolation and oncogenic potential of a novel human src-like gene. Mol Cell Biol 1986;6:4195–201
   PubMedGoogle Scholar
• Ingley E. Src family kinases: regulation of their activities, levels and identification of new pathways. Biochim Biophys Acta 2008;1784:56–65
   PubMed Web of Science ®Google Scholar
• Sudol M, Greulich H, Newman L, et al. A novel Yes-related kinase, Yrk, is expressed at elevated levels in neural and hematopoietic tissues. Oncogene 1993;8:823–31
   PubMed Web of Science ®Google Scholar
• Thomas SM, Brugge JS. Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol 1997;13:513–609
   PubMed Web of Science ®Google Scholar
• Martin GS. The hunting of the Src. Nat Rev Mol Cell Biol 2001;2:467–75
   PubMed Web of Science ®Google Scholar
• Fernandez-Hernandez R, Rafel M, Fuste NP, et al. Cyclin D1 localizes in the cytoplasm of keratinocytes during skin differentiation and regulates cell-matrix adhesion. Cell Cycle 2013;12:2510–7
   PubMed Web of Science ®Google Scholar
• Lipfert L, Haimovich B, Schaller MD, et al. Integrin-dependent phosphorylation and activation of the protein tyrosine kinase pp125FAK in platelets. J Cell Biol 1992;119:905–12
   PubMed Web of Science ®Google Scholar
• Cabodi S, Tinnirello A, Bisaro B, et al. p130Cas is an essential transducer element in ErbB2 transformation. Faseb J 2010;24:3796–808
   Google Scholar
• Sandilands E, Serrels B, McEwan DG, et al. Autophagic targeting of Src promotes cancer cell survival following reduced FAK signalling. Nat Cell Biol 2012;14:51–60
   Google Scholar
• Frame MC. Src in cancer: deregulation and consequences for cell behaviour. Biochim Biophys Acta 2002;1602:114–30
   PubMed Web of Science ®Google Scholar
• Finn RS. Targeting Src in breast cancer. Ann Oncol 2008;19:1379–86
   PubMed Web of Science ®Google Scholar
• Cai H, Smith DA, Memarzadeh S, et al. Differential transformation capacity of Src family kinases during the initiation of prostate cancer. Proc Natl Acad Sci USA 2011;108:6579–84
   PubMed Web of Science ®Google Scholar
• Zhang S, Yu D. Targeting Src family kinases in anti-cancer therapies: turning promise into triumph. Trends Pharmacol Sci 2012;33:122–8
   PubMed Web of Science ®Google Scholar
• Czernilofsky AP, Levinson AD, Varmus HE, et al. Nucleotide sequence of an avian sarcoma virus oncogene (src) and proposed amino acid sequence for gene product. Nature 1980;287:198–203
   PubMed Web of Science ®Google Scholar
• Levinson AD, Oppermann H, Levintow L, et al. Evidence that the transforming gene of avian sarcoma virus encodes a protein kinase associated with a phosphoprotein. Cell 1978;15:561–72
   PubMed Web of Science ®Google Scholar
• Brauer PM, Tyner AL. Building a better understanding of the intracellular tyrosine kinase PTK6 – BRK by BRK. Biochim Biophys Acta 2010;1806:66–73
   PubMed Web of Science ®Google Scholar
• Ostrander JH, Daniel AR, Lange CA. Brk/PTK6 signaling in normal and cancer cell models. Curr Opin Pharmacol 2010;10:662–9
   Google Scholar
• Fan C, Zhao Y, Liu D, et al. Detection of Brk expression in non-small cell lung cancer: clinicopathological relevance. Tumour Biol 2011;32:873–80
   Google Scholar
• Ma S, Bao JY, Kwan PS, et al. Identification of PTK6, via RNA sequencing analysis, as a suppressor of esophageal squamous cell carcinoma. Gastroenterology 2012;143:675–686 e671–612
   Google Scholar
• Liu XK, Zhang XR, Zhong Q, et al. Low expression of PTK6/Brk predicts poor prognosis in patients with laryngeal squamous cell carcinoma. J Transl Med 2013;11:59 . doi: 10.1186/1479-5876-11-59
   Google Scholar
• Derry JJ, Prins GS, Ray V, Tyner AL. Altered localization and activity of the intracellular tyrosine kinase BRK/Sik in prostate tumor cells. Oncogene 2003;22:4212–20
   PubMed Web of Science ®Google Scholar
• Brauer PM, Tyner AL. RAKing in AKT: a tumor suppressor function for the intracellular tyrosine kinase FRK. Cell Cycle 2009;8:2728–32
   PubMed Web of Science ®Google Scholar
• Myers MP, Stolarov JP, Eng C, et al. P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. Proc Nat Acad Sci USA 1997;94:9052–7
   PubMed Web of Science ®Google Scholar
• Yim EK, Peng G, Dai H, et al. Rak functions as a tumor suppressor by regulating PTEN protein stability and function. Cancer Cell 2009;15:304–14
   PubMed Web of Science ®Google Scholar
• Chen JS, Hung WS, Chan HH, et al. In silico identification of oncogenic potential of fyn-related kinase in hepatocellular carcinoma. Bioinformatics 2013;29:420–7
   Google Scholar
• Goel RK, Miah S, Black K, et al. The unique N-terminal region of SRMS regulates enzymatic activity and phosphorylation of its novel substrate docking protein 1. FEBS J 2013;280:4539–59
   Google Scholar
• Whitney GS, Chan PY, Blake J, et al. Human T and B lymphocytes express a structurally conserved focal adhesion kinase, pp125FAK. DNA Cell Biol 1993;12:823–30
   PubMedGoogle Scholar
• Andreev J, Simon JP, Sabatini DD, et al. Identification of a new Pyk2 target protein with Arf-GAP activity. Mol Cell Biol 1999;19:2338–50
   PubMed Web of Science ®Google Scholar
• Clark EA, Brugge JS. Integrins and signal transduction pathways: the road taken. Science 1995;268:233–9
   PubMed Web of Science ®Google Scholar
• Bourne HR. Signal transduction. Team blue sees red. Nature 1995;376:727–9
   PubMedGoogle Scholar
• Schlaepfer DD, Hauck CR, Sieg DJ. Signaling through focal adhesion kinase. Prog Biophys Mol Biol 1999;71:435–78
   PubMed Web of Science ®Google Scholar
• Okada M, Nakagawa H. Identification of a novel protein tyrosine kinase that phosphorylates pp60c-src and regulates its activity in neonatal rat brain. Biochem Biophys Res Commun 1988;154:796–802
   PubMed Web of Science ®Google Scholar
• Sabe H, Knudsen B, Okada M, et al. Molecular cloning and expression of chicken C-terminal Src kinase: lack of stable association with c-Src protein. Proc Natl Acad Sci USA 1992;89:2190–4
   PubMed Web of Science ®Google Scholar
• Tobe K, Sabe H, Yamamoto T, et al. Csk enhances insulin-stimulated dephosphorylation of focal adhesion proteins. Mol Cell Biol 1996;16:4765–72
   PubMed Web of Science ®Google Scholar
• Cao H, Courchesne WE, Mastick CC. A phosphotyrosine-dependent protein interaction screen reveals a role for phosphorylation of caveolin-1 on tyrosine 14: recruitment of C-terminal Src kinase. J Biol Chem 2002;277:8771–4
   PubMed Web of Science ®Google Scholar
• Wong L, Lieser SA, Miyashita O, et al. Coupled motions in the SH2 and kinase domains of Csk control Src phosphorylation. J Mol Biol 2005;351:131–43
   PubMed Web of Science ®Google Scholar
• Chong YP, Mulhern TD, Cheng HC. C-terminal Src kinase (CSK) and CSK-homologous kinase (CHK) - endogenous negative regulators of Src-family protein kinases. Growth Factors 2005;23:233–44
   PubMed Web of Science ®Google Scholar
• Okada M. Regulation of the SRC family kinases by Csk. Int J Biol Sci 2012;8:1385–97
   PubMed Web of Science ®Google Scholar
• Kanou T, Oneyama C, Kawahara K, et al. The transmembrane adaptor Cbp/PAG1 controls the malignant potential of human non-small cell lung cancers that have c-src upregulation. Mol Cancer Res 2011;9:103–14
   Google Scholar
• Masaki T, Okada M, Tokuda M, et al. Reduced C-terminal Src kinase (Csk) activities in hepatocellular carcinoma. Hepatology 1999;29:379–84
   PubMedGoogle Scholar
• Watanabe N, Matsuda S, Kuramochi S, et al. Expression of C-terminal src kinase in human colorectal cancer cell lines. Jpn J Clin Oncol 1995;25:5–9
   PubMedGoogle Scholar
• Tsukada S, Saffran DC, Rawlings DJ, et al. Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell 1993;72:279–90
   PubMed Web of Science ®Google Scholar
• Hussain A, Yu L, Faryal R, et al. TEC family kinases in health and disease–loss-of-function of BTK and ITK and the gain-of-function fusions ITK-SYK and BTK-SYK. FEBS J 2011;278:2001–10
   PubMed Web of Science ®Google Scholar
• Smith CI, Islam TC, Mattsson PT, et al. The Tec family of cytoplasmic tyrosine kinases: mammalian Btk, Bmx, Itk, Tec, Txk and homologs in other species. Bioessays 2001;23:436–46
   PubMed Web of Science ®Google Scholar
• Wang SY, Li FF, Zheng H, et al. Rapid induction and activation of Tec tyrosine kinase in liver regeneration. J Gastroenterol Hepatol 2006;21:668–73
   Google Scholar
• Holopainen T, Lopez-Alpuche V, Zheng W, et al. Deletion of the endothelial Bmx tyrosine kinase decreases tumor angiogenesis and growth. Cancer Res 2012;72:3512–21
   PubMed Web of Science ®Google Scholar
• Fluckiger AC, Li Z, Kato RM, et al. Btk/Tec kinases regulate sustained increases in intracellular Ca2+ following B-cell receptor activation. Embo J 1998;17:1973–85
   PubMed Web of Science ®Google Scholar
• Lin J, Weiss A. T cell receptor signalling. J Cell Sci 2001;114:243–4
   PubMed Web of Science ®Google Scholar
• Lewis CM, Broussard C, Czar MJ, Schwartzberg PL. Tec kinases: modulators of lymphocyte signaling and development. Curr Opin Immunol 2001;13:317–25
   Google Scholar
• Ting AY, Kain KH, Klemke RL, Tsien RY. Genetically encoded fluorescent reporters of protein tyrosine kinase activities in living cells. Proc Natl Acad Sci U S A 2001;98:15003–8
   PubMed Web of Science ®Google Scholar
• Buccione R, Orth JD, McNiven MA. Foot and mouth: podosomes, invadopodia and circular dorsal ruffles. Nat Rev Mol Cell Biol 2004;5:647–57
   PubMed Web of Science ®Google Scholar
• Pendergast AM. The Abl family kinases: mechanisms of regulation and signaling. Adv Cancer Res 2002;85:51–100
   PubMed Web of Science ®Google Scholar
• Woodring PJ, Litwack ED, O'Leary DD, et al. Modulation of the F-actin cytoskeleton by c-Abl tyrosine kinase in cell spreading and neurite extension. J Cell Biol 2002;156:879–92
   PubMed Web of Science ®Google Scholar
• Colicelli J. ABL tyrosine kinases: evolution of function, regulation, and specificity. Sci Signa. 2010;3:re6 . doi: 10.1126/scisignal.3139re6
   PubMedGoogle Scholar
• Griaud F, Williamson AJ, Taylor S, et al. BCR/ABL modulates protein phosphorylation associated with the etoposide-induced DNA damage response. J Proteomics 2012;77:14–26
   Google Scholar
• Srinivasan D, Plattner R. Activation of Abl tyrosine kinases promotes invasion of aggressive breast cancer cells. Cancer Res 2006;66:5648–55
   PubMed Web of Science ®Google Scholar
• Sirvent A, Boureux A, Simon V, et al. The tyrosine kinase Abl is required for Src-transforming activity in mouse fibroblasts and human breast cancer cells. Oncogene 2007;26:7313–23
   PubMedGoogle Scholar
• Chen WS, Kung HJ, Yang WK, Lin W. Comparative tyrosine-kinase profiles in colorectal cancers: enhanced arg expression in carcinoma as compared with adenoma and normal mucosa. Int J Cancer 1999;83:579–84
   PubMed Web of Science ®Google Scholar
• Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007;131:1190–203
   PubMed Web of Science ®Google Scholar
• Buschbeck M, Hofbauer S, Di Croce L, et al. Abl-kinase-sensitive levels of ERK5 and its intrinsic basal activity contribute to leukaemia cell survival. EMBO Rep 2005;6:63–9
   PubMedGoogle Scholar
• Mulloy R, Salinas S, Philips A, Hipskind RA. Activation of cyclin D1 expression by the ERK5 cascade. Oncogene 2003;22:5387–98
   Google Scholar
• Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 2005;5:172–83
   PubMed Web of Science ®Google Scholar
• Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005;105:2640–53
   PubMed Web of Science ®Google Scholar
• Holdhoff M, Kreuzer KA, Appelt C, et al. Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor. Blood Cells Mol Dis 2005;34:181–5
   PubMedGoogle Scholar
• Heinrich MC, Griffith DJ, Druker BJ, et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000;96:925–32
   PubMed Web of Science ®Google Scholar
• Tuveson DA, Willis NA, Jacks T, et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 2001;20:5054–8
   PubMed Web of Science ®Google Scholar
• Dewar AL, Cambareri AC, Zannettino AC, et al. Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood 2005;105:3127–32
   PubMed Web of Science ®Google Scholar
• Dickerson EB, Marley K, Edris W, et al. Imatinib and dasatinib inhibit hemangiosarcoma and implicate PDGFR-beta and Src in tumor growth. Transl Oncol 2013;6:158–68
   Google Scholar
• Lombardo LJ, Lee FY, Chen P, et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004;47:6658–61
   PubMed Web of Science ®Google Scholar
• Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood 2008;112:4808–17
   PubMed Web of Science ®Google Scholar
• Greuber EK, Smith-Pearson P, Wang J, Pendergast AM. Role of ABL family kinases in cancer: from leukaemia to solid tumours. Nat Rev Cancer 2013;13:559–71
   PubMed Web of Science ®Google Scholar
• Yanagi S, Inatome R, Takano T, Yamamura H. Syk expression and novel function in a wide variety of tissues. Biochem Biophys Res Commun 2001;288:495–8
   PubMed Web of Science ®Google Scholar
• Palacios EH, Weiss A. Distinct roles for Syk and ZAP-70 during early thymocyte development. J Exp Med 2007;204:1703–15
   PubMedGoogle Scholar
• Corey SJ, Burkhardt AL, Bolen JB, et al. Granulocyte colony-stimulating factor receptor signaling involves the formation of a three-component complex with Lyn and Syk protein-tyrosine kinases. Proc Nat Acad Sci U S A 1994;91:4683–7
   PubMed Web of Science ®Google Scholar
• Chen L, Monti S, Juszczynski P, et al. SYK inhibition modulates distinct PI3K/AKT- dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas. Cancer Cell 2013;23:826–38
   PubMed Web of Science ®Google Scholar
• Ungureanu D, Wu J, Pekkala T, et al. The pseudokinase domain of Jak2 is a dual-specificity protein kinase that negatively regulates cytokine signaling. Nat Struct Mol Biol 2011;18:971–6
   PubMedGoogle Scholar
• Yu H, Jove R. The STATs of cancer–new molecular targets come of age. Nat Rev Cancer 2004;4:97–105
   PubMed Web of Science ®Google Scholar
• Baker SJ, Rane SG, Reddy EP. Hematopoietic cytokine receptor signaling. Oncogene 2007;26:6724–37
   PubMed Web of Science ®Google Scholar
• Jatiani SS, Baker SJ, Silverman LR, Reddy EP. Jak/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies. Genes Cancer 2010;1:979–93
   PubMedGoogle Scholar
• Vainchenker W, Constantinescu SN. Jak/STAT signaling in hematological malignancies. Oncogene 2013;32:2601–13
   PubMed Web of Science ®Google Scholar
• Vainchenker W, Dusa A, Constantinescu SN. Jaks in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies. Semin Cell Dev Biol 2008;19:385–93
   PubMed Web of Science ®Google Scholar
• LaFave LM, Levine RL. Jak2 the future: therapeutic strategies for Jak-dependent malignancies. Trends in pharmacological sciences 2012;33:574–82
   PubMed Web of Science ®Google Scholar
• Waters MJ, Brooks AJ. Growth hormone and cell growth. Endocr Dev. 2012;23:86–95
   Google Scholar
• Hayashi AA, Proud CG. The rapid activation of protein synthesis by growth hormone requires signaling through mTOR. Am J Physiol Endocrinol Metab 2007;292:E1647–55
   PubMed Web of Science ®Google Scholar
• Denver RJ, Bonett RM, Boorse GC. Evolution of leptin structure and function. Neuroendocrinology 2011;94:21–38
   PubMed Web of Science ®Google Scholar
• Vecchio L, Seke Etet PF, Kipanyula MJ, et al. Importance of epigenetic changes in cancer etiology, pathogenesis, clinical profiling, and treatment: what can be learned from hematologic malignancies? Biochim Biophys Acta 2013;1836:90–104
   Google Scholar
• Ubel C, Mousset S, Trufa D, et al. Establishing the role of tyrosine kinase 2 in cancer. Oncoimmunology 2013;2:e22840
   PubMed Web of Science ®Google Scholar
• Stark GR, Darnell JE, Jr. The Jak-STAT pathway at twenty. Immunity 2012;36:503–14
   PubMed Web of Science ®Google Scholar
• Craig AW. FES/FER kinase signaling in hematopoietic cells and leukemias. Front Biosci (Landmark Ed) 2012;17:861–75
   Google Scholar
• Kanda S, Miyata Y, Kanetake H, Smithgall TE. Non-receptor protein-tyrosine kinases as molecular targets for antiangiogenic therapy (Review). Int J Mol Med 2007;20:113–21
   PubMedGoogle Scholar
• Swords R, Freeman C, Giles F. Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia. Leukemia 2012;26:2176–85
   PubMed Web of Science ®Google Scholar
• Yokota S, Kiyoi H, Nakao M, et al. Internal tandem duplication of the Flt3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia 1997;11:1605–9
   PubMed Web of Science ®Google Scholar
• Choudhary C, Muller-Tidow C, Berdel WE, Serve H. Signal transduction of oncogenic Flt3. Int J Hematol 2005;82:93–9
   PubMed Web of Science ®Google Scholar
• Weisberg E, Barrett R, Liu Q, et al. Flt3 inhibition and mechanisms of drug resistance in mutant Flt3-positive AML. Drug Resist Updat 2009;12:81–9
   PubMed Web of Science ®Google Scholar
• Takahashi S. Downstream molecular pathways of Flt3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications. J Hematol Oncol 2011;4:13. doi: 10.1186/1756-8722-4-13
   PubMed Web of Science ®Google Scholar
• Voisset E, Lopez S, Chaix A, et al. FES kinases are required for oncogenic Flt3 signaling. Leukemia 2010;24:721–8
   PubMed Web of Science ®Google Scholar
• Galisteo ML, Yang Y, Urena J, Schlessinger J. Activation of the nonreceptor protein tyrosine kinase Ack by multiple extracellular stimuli. Proc Nat Acad Sci USA 2006;103:9796–801
   PubMed Web of Science ®Google Scholar
• Howlin J, Rosenkvist J, Andersson T. TNK2 preserves epidermal growth factor receptor expression on the cell surface and enhances migration and invasion of human breast cancer cells. Breast Cancer Res 2008;10:R36. doi: 10.1186/bcr2087
   Web of Science ®Google Scholar
• Prieto-Echague V, Gucwa A, Craddock BP, et al. Cancer-associated mutations activate the nonreceptor tyrosine kinase Ack1. J Biol Chem 2010;285:10605–15
   PubMed Web of Science ®Google Scholar
• Chan W, Sit ST, Manser E. The Cdc42-associated kinase ACK1 is not autoinhibited but requires Src for activation. Biochem J 2011;435:355–64
   PubMedGoogle Scholar
• Modzelewska K, Newman LP, Desai R, Keely PJ. Ack1 mediates Cdc42-dependent cell migration and signaling to p130Cas. J Biol Chem 2006;281:37527–35
   PubMed Web of Science ®Google Scholar
• van der Horst EH, Degenhardt YY, Strelow A, et al. Metastatic properties and genomic amplification of the tyrosine kinase gene ACK1. Proc Nat Acad Sci USA 2005;102:15901–6
   PubMed Web of Science ®Google Scholar
• May WS, Hoare K, Hoare S, et al. Tnk1/Kos1: a novel tumor suppressor. Trans Am Clin Climatol Assoc 2010;121:281–92
   Google Scholar
• Feller SM. Tony (Anthony James) Pawson, a giant in the field of cell signaling research, dies unexpectedly at the age of 60. Cell Commun Signal 2013;11:61. doi: 10.1186/1478-811X-11-61
   Google Scholar
• O'Hare T, Deininger MW, Eide CA, et al. Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia. Clin Cancer Res 2011;17:212–21
   PubMed Web of Science ®Google Scholar
• Shah NP, Kasap C, Weier C, et al. Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell 2008;14:485–93
   PubMed Web of Science ®Google Scholar
• Leder K, Foo J, Skaggs B, et al. Fitness conferred by BCR-ABL kinase domain mutations determines the risk of pre-existing resistance in chronic myeloid leukemia. PLoS One 2011;6:e27682
   Web of Science ®Google Scholar